BioSpace News Archive

In two clinical studies (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), VYEPTI met its primary endpoint: decrease in mean monthly migraine days (MMD) over months 1-3.

Zhongchao Inc. announced the pricing of its initial public offering of 3,000,000 Class A ordinary shares at a public offering price of $4.00 per share.

With coaching from BioGenerator’s unique Grants-2-Business program, St. Louis bioscience startup VaxNewMo has earned $3 million in federal grant funding to advance the company’s development of a next-generation vaccine to combat pneumococcus, the most common cause of bloodstream infections, pneumonia, meningitis, and middle ear infections.

Israel’s Sheba Medical Center, Tel HaShomer has confirmed the first case of coronavirus after 11 Israeli travelers from the Princess Diamond cruise ship were brought to an isolated unit at Sheba on Friday morning.

The Chief Public Health Officer, Dr. Theresa Tam, and the Deputy Chief Public Health Officer, Dr. Howard Njoo, will hold a media availability to provide an update on the novel coronavirus..

Dr. Scott Hacker announced today that he has treated his tenth patient in the ongoing Phase 3 clinical trial of NOVOCART 3D, an investigational autologous chondrocyte transplantation system designed to treat articular cartilage defects of the knee.

Bench International, a leading global executive search firm, announces the opening of a new regional office located in the heart of San Diego’s life science community.

As concern over potential transmission of the Coronavirus to healthcare workers treating afflicted patients continues to rise, industry expert Radiation Shield Technologies is issuing a call-to-action to ensure healthcare workers have access to the necessary personal-protection gear.

Aurinia Pharmaceuticals Inc. announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at 10:00 a.m. ET in New York, NY.

Arena Pharmaceuticals, Inc. announced that on February 10, 2020 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 132,100 shares of its common stock to 20 new employees.